Inclusion Criteria:

- Complete 6 cycles treatment in preceding phase I/II study

- response (CR, PR, MR or NC) was obtained in 6 cycles treatment during the preceding
phase I/II study and investigator considers that the patient is expected to have
benefit such as antitumor effect, pain relief or improvement of performance state

- Patients who did not have Grade >=3 non-hematologic toxicity or Grade 4 hematologic
toxicity during the preceding phase I/II study or extension treatment of this study

- Investigator considers that the patient is expected to have benefit of this drug such
as antitumor effect, pain relief or improvement of performance state.

Exclusion Criteria:

- Patient is known to be HBs antigen positive, HCV antibody positive or HIV antibody
positive (check is required for patients who received blood product during phase I/II
study)

- Patients who receive G-CSF product or blood transfusion within 7 days before the
start of treatment

- Disease progress was observed during the phase I/II or this study when patients
receive recommended dose

- Patients who suffer Grade >=2 peripheral neuropathy or Grade >=2 neuropathic pain

- Patient has New York Heart Association (NYHA) Class III or IV heart failure,
uncontrolled angina, severe uncontrolled ventricular arrhythmias, acute ischemia or
active conduction system abnormalities.